|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.08 HKD | +1.77% |
|
-2.35% | +24.24% |
| 01-16 | WuXi Biologics Shareholder to Sell Shares | MT |
| 01-16 | Wuxi Biologics (Cayman) says Wuxi Biologics Holdings enters block trade agreement with Morgan Stanley | RE |
| Capitalization | 142B 159B 20.36B 17.41B 16.16B 15.15B 28.11B 1,865B 30.1B 185B 73.38B 881B 76.34B 74.78B 3,219B | P/E ratio 2025 * |
31.8x | P/E ratio 2026 * | 28x |
|---|---|---|---|---|---|
| Enterprise value | 135B 151B 19.39B 16.58B 15.39B 14.43B 26.77B 1,776B 28.67B 177B 69.88B 839B 72.7B 71.22B 3,066B | EV / Sales 2025 * |
6.27x | EV / Sales 2026 * | 5.34x |
| Free-Float |
86.37% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | +1.72% | ||
| 1 week | -2.35% | ||
| Current month | +24.24% | ||
| 1 month | +17.86% | ||
| 3 months | +8.44% | ||
| 6 months | +39.50% | ||
| Current year | +24.24% |
| 1 week | 36.68 |  | 40.4 |
| 1 month | 31.1 | | 40.4 |
| Current year | 31.1 | | 40.4 |
| 1 year | 16.2 | | 42.6 |
| 3 years | 10.14 | | 72.5 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 54 | 01/01/2016 |
Ming Tu
DFI | Director of Finance/CFO | 56 | 23/08/2021 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 58 | 01/02/2014 |
Zhi Sheng Chen
BRD | Director/Board Member | 54 | 01/02/2014 |
Yan Ling Cao
BRD | Director/Board Member | 42 | 01/05/2016 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.27% | 2.99% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.77% | -2.35% | +114.62% | -45.29% | 20.36B | |
| +1.49% | -0.14% | +9.71% | +95.78% | 49.82B | |
| -0.91% | -4.69% | +77.60% | +1.08% | 42.19B | |
| -4.40% | -4.37% | +103.67% | +648.66% | 33.34B | |
| +11.78% | +8.14% | +0.64% | -17.36% | 29.61B | |
| +4.50% | -2.70% | +38.28% | -23.80% | 20.15B | |
| -2.11% | -9.56% | +89.96% | +120.99% | 13.47B | |
| -3.54% | -11.19% | +160.34% | - | 12.84B | |
| +4.92% | -4.53% | -23.76% | +283.83% | 12.99B | |
| Average | +0.14% | -3.52% | +63.45% | +132.99% | 26.08B | |
| Weighted average by Cap. | -0.03% | -2.39% | +56.65% | +134.48% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 21.53B 24.1B 3.09B 2.64B 2.45B 2.3B 4.27B 283B 4.57B 28.16B 11.14B 134B 11.59B 11.36B 489B | 25B 27.99B 3.59B 3.07B 2.85B 2.67B 4.96B 329B 5.31B 32.7B 12.94B 155B 13.46B 13.19B 568B |
| Net income | 4.46B 4.99B 641M 548M 508M 477M 885M 58.67B 947M 5.83B 2.31B 27.73B 2.4B 2.35B 101B | 5.06B 5.67B 727M 622M 577M 541M 1B 66.59B 1.07B 6.62B 2.62B 31.47B 2.73B 2.67B 115B |
| Net Debt | -6.75B -7.56B -970M -829M -770M -722M -1.34B -88.82B -1.43B -8.83B -3.5B -41.98B -3.64B -3.56B -153B | -8.27B -9.26B -1.19B -1.02B -943M -884M -1.64B -109B -1.76B -10.82B -4.28B -51.43B -4.46B -4.36B -188B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/01/26 | 39.08 $ | +1.77% | 26,355,044 |
| 21/01/26 | 38.40 $ | +3.50% | 29,655,920 |
| 20/01/26 | 37.10 $ | -2.01% | 28,301,690 |
| 19/01/26 | 37.86 $ | -4.83% | 41,306,910 |
| 16/01/26 | 39.78 $ | -0.60% | 219,334,000 |
Delayed Quote Hong Kong S.E., January 22, 2026 at 02:49 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition